



**TISSEEL**  
*[Fibrin Sealant]*

Introducing  
**PRIMA**

*Next Generation Pre-filled Syringe*

SPEED,  
**PRECISION**  
& **CONTROL**



**Baxter**



**TISSEEL**  
[Fibrin Sealant]

The same trusted **TISSEEL**,  
Now with Next Generation **PRIMA** syringe

**17% QUICKER**  
THAWING TIME\*

The TISSEEL PRIMA syringe thaws 17% faster – getting the product in your hands more quickly<sup>1</sup>

**8X EASIER**  
TO PUSH\*\*

The TISSEEL PRIMA syringe is 8 times easier to push – supporting a higher level of precision and control during surgery<sup>2</sup>

**USER-FRIENDLY,**  
FULLY ASSEMBLED SYRINGE

The TISSEEL PRIMA syringe comes fully assembled – allowing you greater control and faster time to table<sup>1</sup>



\*vs. legacy 10mL syringe using sterile water bath, thawed at 33-37°C

\*\*vs. legacy 10mL syringe

TISSEEL Fibrin Sealant Benefits:

# 5X MORE COVERAGE USING DUPLOSPRAY


TISSEEL provides five times more spray coverage than EVICEL, maximizing your ability to control bleeding across broad surfaces<sup>3,4</sup>

TOTAL VOLUME	TISSEEL	EVICEL
2 mL	100 cm <sup>2</sup>	20 cm <sup>2</sup>
4 mL	200 cm <sup>2</sup>	40 cm <sup>2</sup>
10 mL	500 cm <sup>2</sup>	100 cm <sup>2</sup>

## 10-14 DAYS TIME TO RESORPTION

TISSEEL forms a clot that remains in the body for 10-14 days before being fully resorbed by the human body<sup>3</sup>

Hemostatic agents comprised of polysaccharide, like ARISTA, are typically resorbed by the human body in approximately 24-48 hours<sup>5</sup>



## WIDE RANGE OF APPLICATORS

TISSEEL provides a wide range of applicators, giving you the ability to customize the delivery of TISSEEL to your bleeding site<sup>3</sup>

**DUPLOSPRAY**  
20cm, 30cm, 40cm

**DUPLOTIP**  
10cm, 26cm, 32cm, 40cm

Flexible 360°

SNAP to Secure

**SNAP**  
and  
**ON USE!**



# TISSEEL PRIMA SYRINGE

DESCRIPTION	PER PACK	CODES
TISSEEL PRIMA SYRINGE 2mL	1 EA	1506078
TISSEEL PRIMA SYRINGE 4mL	1 EA	1506079
TISSEEL PRIMA SYRINGE 10mL	1 EA	1506080

## APPLICATORS

DESCRIPTION	PER PACK	CODES
DUPLOTIP WITH SNAP LOCK 20G X 10CM	10/PK	0601136
DUPLOTIP WITH SNAP LOCK 20G X 26CM	10/PK	0601137
DUPLOTIP WITH SNAP LOCK 5MM X 32CM	10/PK	0601138
<b>NEW</b> DUPLOTIP RIGID WITH SNAP LOCK 5MM X 40CM	3/PK	0601139
DUPLOSPRAY MIS APPLICATOR WITH SNAP LOCK 20CM	5/PK	0601133
DUPLOSPRAY MIS APPLICATOR WITH SNAP LOCK 30CM	5/PK	0601129
DUPLOSPRAY MIS APPLICATOR WITH SNAP LOCK 40CM	5/PK	0601130
SPRAY SET 360 ENDOSCOPIC APPLICATOR WITH SNAP LOCK	5/PK	SA3768111

### TISSEEL [Fibrin Sealant] Indications

Hemostasis: TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (> 1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.

Sealing: TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies.

### Important Risk Information for TISSEEL[Fibrin Sealant]

For Topical Use Only. Do not inject TISSEEL directly into the circulatory system or into highly vascularized tissue. Intravascular application of TISSEEL can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients. To minimize the risk of intravascular application, exercise caution when using TISSEEL in surgery.

Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin. Do not use TISSEEL for treatment of severe or brisk arterial or venous bleeding. In these situations, TISSEEL will be washed away in the flow of blood before hemostasis can be attained.

Do not spray TISSEEL where the minimum recommended distance from the applicator tip to the target site cannot be assured.

Hypersensitivity or allergic/anaphylactoid reactions can occur with the use of TISSEEL. Such reactions may especially be seen if TISSEEL is applied repeatedly over time or in the same setting, or if systemic aprotinin has been administered previously.

Aprotinin is known to be associated with anaphylactic reactions. Even in the case of strict local application of aprotinin, there is a risk of anaphylactic reactions to aprotinin, particularly in the case of previous exposure.

Discontinue administration of TISSEEL in the event of hypersensitivity reactions. Remove remaining product from the application site.

Air or gas embolism has occurred when fibrin sealant was administered using pressurized gas. This can occur if a spray device is used at higher than recommended pressures and in closer than recommended proximity to the tissue surface.

When using the EASYSpray device, or an equivalent spray device for open surgical procedures cleared by FDA, TISSEEL must not be sprayed in enclosed body areas and must be sprayed onto only visible application sites.

TISSEEL is denatured when exposing to solutions containing alcohol, iodine or heavy metals. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.

Apply TISSEEL as a thin layer by dripping or spraying using cannula or spray set. Excess clot thickness can negatively interfere with wound healing.

The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated; its use in this setting is not FDA approved.

TISSEEL is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying full Prescribing Information.

## References

1. TISSEEL [Summary of Product Characteristics]. Vienna, Austria: Baxter International Inc. 2016
2. Baxter Data on File
3. TISSEEL Fibrin Sealant Frozen Solution and Lyophilized Powder [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. Revised 11 Nov 2014.
4. EVICEL Fibrin Sealant (Human) [Prescribing Information]. Somerville, NJ, USA: ETHICON, Inc.; 2014.
5. ARISTA IFU Warwick, RI: C.R. Bard, Inc., 2015.

Baxter, Duplocath, Duploject, Duplospray, Duplotip, EasySpray, and Tisseel are trademarks of Baxter International Inc.

Arista is a registered trademark of Medafor, Inc.

Evicel is a registered trademark of Johnson & Johnson Corporation.

USMP/90/18-0036 11/2018